Congratulation to Co-Editor in Chief, Prof Heidi Abrahamse who received the 2019 Humanitarian Award at the 17th World Congress of the International Photodynamic Association in Boston, MA
https://t.co/O3sYw78aIv
The new 2018 Impact Factor for Photobiomodulation, Photomedicine and Laser Surgery is 1.913. This represents an impressive increase (18%) from 1.620 in 2017, taking us closer to an IF of 2.0. This reflects papers published in calendar years 2016 and 2017 that were cited in 2018.
Another recently accepted paper
PHO-2018-4611.R2
Comparative In Vitro Study: Examining 635 nm Laser and 265 nm UV Interaction with Blood
M. A. Elblbesy
Received: December 19, 2018.
Accepted After Revision: January 30, 2019.
Latest accepted paper
PHO 2018-4533.R3
Photobiomodulation Therapy Versus Extracorporeal Shock Wave Therapy in the Treatment of Lateral Epicondylitis
D. Celik, and B. Anaforoglu Kulunkoglu
Received: July 17, 2018.
Accepted After Revision: February 1, 2019.
Editor-in-Chief Mike Hamblin invites you to read this important article that attempts to unify the terminology used in photobiomodulation and photobiomodulation therapy.
https://t.co/SoE6RdJZQ6
Paolo Cassano's new paper used photobiomodulation to treat major depressive disorder in the ELATED2 pilot clinical trial with a "medium to large effect size"
https://t.co/EnhxFxAqQ3
The new editorial board of Photobiomodulation, Photomedicine, Laser Surgery is now available on the journal website. Thank you all for accepting the invitations.
https://t.co/SVBQRj7R5k
The new editorial board of Photobiomodulation, Photomedicine, Laser Surgery is now available on the journal website. Thank you all for accepting the invitations.
https://t.co/SVBQRj7R5k
"Photobiomodulation, Photomedicine, Laser Surgery" will be the new name of the journal Photomedicine and Laser Surgery with a new Editor-in-Chief, Michael R Hamblin PhD from Mass General Hospital and Harvard Medical School